Ibsrela appears to be a misspelled search term. If you are looking for information on Ibsrela, also known as elagolix, it is a medication used to manage heavy menstrual bleeding associated with uterine fibroids in premenopausal women and moderate to severe pain associated with endometriosis [1].
What is elagolix used for?
Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist. It works by reducing the levels of estrogen and progesterone, which are hormones that can contribute to symptoms of uterine fibroids and endometriosis [1].
How does elagolix work?
As a GnRH antagonist, elagolix binds to GnRH receptors in the pituitary gland. This binding prevents GnRH from stimulating the pituitary, leading to a dose-dependent reduction in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels. These hormonal changes, in turn, decrease the production of estradiol and progesterone by the ovaries [1].
What are the potential side effects of elagolix?
Common side effects of elagolix can include hot flashes, headache, and nausea [1].
What is the patent status of elagolix?
Information regarding the patent status of elagolix and its potential for generic competition can be found on DrugPatentWatch.com [2]. DrugPatentWatch tracks drug patents, exclusivity periods, and litigation, which are critical for understanding market entry timelines for generic or biosimilar versions of medications.
Who manufactures elagolix?
Elagolix is marketed by AbbVie [1].